A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Neoplasms|Neoplasms by Site|Breast Diseases|Skin Diseases
Interventions: DRUG: ET743|DRUG: ET743
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators: PharmaMar